Literature DB >> 2451948

Use of a monoclonal antibody (GA3) to demonstrate lineage restricted O-glycosylation on leukosialin during terminal erythroid differentiation.

A Bettaieb1, F Farace, M T Mitjavila, Z Mishal, M C Dokhelar, T Tursz, J Breton-Gorius, W Vainchenker, N Kieffer.   

Abstract

A murine monoclonal antibody (GA3) obtained by immunizing mice with cells of the human erythroleukemic cell line K562 is shown to define a 105 kilodalton (kd) membrane antigen on K562 cells that is restricted within the hematopoietic system to the erythroid lineage and to a minor population of CD3, CD4 positive T lymphocytes. Cocapping studies and immunoprecipitation experiments performed with GA3 and L10, an anti-sialophorin monoclonal antibody reacting with leukosialin (Gp 105) on K562 cells, demonstrate that the antigen detected by GA3 on K562 cells is identical to leukosialin. Neuraminidase treatment but not tunicamycin treatment of K562 cells abolishes the expression of the GA3-epitope without affecting the L10-epitope thus providing evidence that terminal sialic acid present on O-linked oligosaccharide chains on Gp 105 is essential for the expression of the GA3-epitope. Further analysis by flow cytometry and immune panning experiments performed on bone marrow cells with GA3 or L10 demonstrate that, in contrast to L10, which reacts with all types of hematopoietic progenitors, the epitope recognized by GA3 is restricted to the erythroid lineage, and appears during erythroid differentiation before glycophorin A on the earliest morphologically recognizable erythroid precursor, the proerythroblast. Our results therefore suggest that O-linked oligosaccharides on leukosialin express lineage restricted and even maturation restricted antigenic structures that might serve as cell lineage specific markers.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2451948

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Identification and tissue distribution of rabbit leucocyte antigens recognized by monoclonal antibodies.

Authors:  J M Wilkinson; J Galea-Lauri; R A Sellars; C Boniface
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

Review 2.  Molecular characterization of CD34+ human hematopoietic progenitor cells.

Authors:  W Knapp; H Strobl; C Scheinecker; C Bello-Fernandez; O Majdic
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

3.  An antiserum raised against the recombinant cytoplasmic tail of the human CD43 glycoprotein identifies CD43 in many mammalian species.

Authors:  T Szlanka; G K Toth; I Ocsovszki; G Keresztes
Journal:  Immunology       Date:  1999-01       Impact factor: 7.397

4.  Methyl-CpG-binding protein MeCP2 represses Sp1-activated transcription of the human leukosialin gene when the promoter is methylated.

Authors:  S Kudo
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

5.  Zinc transporters ZnT1 (Slc30a1), Zip8 (Slc39a8), and Zip10 (Slc39a10) in mouse red blood cells are differentially regulated during erythroid development and by dietary zinc deficiency.

Authors:  Moon-Suhn Ryu; Louis A Lichten; Juan P Liuzzi; Robert J Cousins
Journal:  J Nutr       Date:  2008-11       Impact factor: 4.798

6.  Differential epitope expression of Ly-48 (mouse leukosialin).

Authors:  C M Baecher-Allan; J D Kemp; K S Dorfman; R K Barth; J G Frelinger
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

7.  Characterization of cDNAs encoding human leukosialin and localization of the leukosialin gene to chromosome 16.

Authors:  A Pallant; A Eskenazi; M G Mattei; R E Fournier; S R Carlsson; M Fukuda; J G Frelinger
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

8.  The dimensions of the T lymphocyte glycoprotein leukosialin and identification of linear protein epitopes that can be modified by glycosylation.

Authors:  J G Cyster; D M Shotton; A F Williams
Journal:  EMBO J       Date:  1991-04       Impact factor: 11.598

9.  Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow.

Authors:  R R Hardy; C E Carmack; S A Shinton; J D Kemp; K Hayakawa
Journal:  J Exp Med       Date:  1991-05-01       Impact factor: 14.307

Review 10.  Valid Presumption of Shiga Toxin-Mediated Damage of Developing Erythrocytes in EHEC-Associated Hemolytic Uremic Syndrome.

Authors:  Johanna Detzner; Gottfried Pohlentz; Johannes Müthing
Journal:  Toxins (Basel)       Date:  2020-06-04       Impact factor: 4.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.